EASD SEESAW 31 3 2020.pdf (334.3 kB)
The SGLT2 inhibitor empagliflozin does not stimulate compensatory appetite responses in patients with excess adiposity and type 2 diabetes [Abstract]
conference contribution
posted on 2020-12-10, 16:42 authored by Melanie Davies, Emma Baldry, Danielle Bodicoat, Sudesna Chatterjee, Charlotte Edwardson, Laura Gray, Kamlesh Khunti, Jack Sargeant, David StenselDavid Stensel, David Webb, John Wilding, Scott WillisScott Willis, Tom Yates, James KingJames KingNo description supplied
History
School
- Sport, Exercise and Health Sciences
Published in
DiabetologiaVolume
63Issue
Suppl 1Pages
S116 - S116Source
56th Annual Meeting of the European Association for the Study of Diabetes (EASD 2020)Publisher
SpringerVersion
- AM (Accepted Manuscript)
Rights holder
© Springer-Verlag GmbH Germany, part of Springer NaturePublisher statement
This is a post-peer-review, pre-copyedit version of an article published in Diabetologia. The final authenticated version is available online at: https://doi.org/10.1007/s00125-020-05221-5.Acceptance date
2020-05-27Publication date
2020-08-25Copyright date
2020ISSN
0012-186XeISSN
1432-0428Publisher version
Language
- en
Location
ViennaEvent dates
21st September 2020 - 25th September 2020Depositor
Dr James King Deposit date: 27 May 2020Article number
230Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC